Custom Cast | Figure 1

Custom Cast: A Figure1 Podcast

Latest Episode

Examining the Complexities of Diagnosing Lennox-Gastaut Syndrome

For patients with hard-to-treat epilepsies, a syndrome-specific diagnosis is crucial to ensuring they receive the best possible care, including access to antiseizure medications (ASMs). But some epilepsies evolve and seem more elusive as patients reach adolescence or adulthood. In this final episode of the podcast series, epilepsy experts David Burdette, MD, and Ann Hyslop Segeren, MD, examine how a clear, clinical diagnosis can facilitate appropriate treatment regimens for pediatric and adult patients. They review consensus recommendations for identifying symptoms, navigating historical data, and utilizing resources developed by experts for use by healthcare providers in any diagnostic setting.

The basis of this series is a publication in the journal Epilepsia Open. This podcast is sponsored by Jazz Pharmaceuticals and is for US prescribers only. It is intended for informational purposes only and is not a substitute for clinical knowledge or professional judgment. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on this podcast. Podcast presenters are paid consultants for Jazz Pharmaceuticals. There are no certified continued medical education credits approved for the podcast. ©2026 Jazz Pharmaceuticals plc or its subsidiaries. All rights reserved. US-EPX-2500227

Welcome to a special 3-part Figure 1 podcast series about personalizing care for treatment-resistant epilepsies.

In this series, we hear from two epilepsy experts who participated in the development of Consensus Recommendations for optimizing an antiseizure medication (ASM) for patients with hard-to-treat epilepsy. This series will cover topics including diagnosis, dosing optimization, balancing efficacy and tolerability, and concomitant use of multiple ASMs.